abstract |
The present invention relates to the use of the A20-binding inhibitor of NF-κB activation (ABIN), or a functional fragment or variant thereof to protect aGalNst TNF-induced liver failure, such as viral hepatitis and alcoholic liver disease. More particularly, it relates to the prevention of the toxic effects of said diseases, including lethality, by overexpressing ABIN. |